York Pharma

York Pharma is an AIM-listed strategic acquirer, developer and marketer of pharmaceutical products in the field of dermatology. Its portfolio now targets skin diseases that make up approximately 75% of the global $10.4bn dermatology market. The Company's lead product, Abasol, is an entirely new compound for the treatment of fungal infections of the skin.

RTI holds 1.8m shares or 3.74% interest in York Pharma. RTI also holds 150,000 warrants in the Company.